Business
RINVOQ® (upadacitinib) Receives Health Canada Notice of Compliance (NOC) for Giant Cell Arteritis in adults
AbbVie today announced that Health Canada has issued a Notice of Compliance for RINVOQ® (upadacitinib) for the treatment of adults with giant cell arteritis (GCA), both used in combination with a tapering course of corticosteroids and as monotherapy following discontinuation of corticosteroids.4
About this update from Abbvie Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"RINVOQ is the first and only oral advanced therapy approved for the treatment of giant cell arteritis (GCA) in Canadian adults1","length":127,"tagName":"p"}]},{"val":[{"type":"text","content":"GCA is the most common vasculitis in Canada, primarily affecting adults over 502","length":80,"tagName":"p"}]},{"val":[{"type":"text","content":"This marks the eighth approved indication for RINVOQ in Canada across rheumatology, gastroenterology and dermatology3","length":122,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":329,"olType":false},{"type":"text","content":"MONTREAL, Aug. 27, 2025 /CNW/ - AbbVie today announced that Health Canada has issued a Notice of Compliance for RINVOQ® (upadacitinib) for the treatment of adults with giant cell arteritis (GCA), both used in combination with a tapering course of corticosteroids and as monotherapy following discontinuation of corticosteroids.4 ","length":328,"tagName":"p"},{"type":"image","alt":"AbbVie Canada Logo (CNW Group/AbbVie Canada)","displaySize":"","headline":null,"caption":"AbbVie Canada Logo (CNW Group/AbbVie Canada)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":78,"url":"https://media.zenfs.com/en/cnwgroup.com/81a95d8e7cb129c0fcb522eb9b4bf1e8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4KWP37hq1mHN3nhM7UjA1Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEzNztjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/81a95d8e7cb129c0fcb522eb9b4bf1e8","width":400,"height":78}},"href":"https://mma.prnewswire.com/media/2757616/AbbVie_Canada_RINVOQ_%C2%A0_upadacitinib__Receives_Health_Canada_Noti.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"GCA is a chronic autoimmune vasculitis that causes inflammation of the temporal and other cranial arteries, the aorta and its major branches. It is estimated that thousands of Canadians over the age of 50, primarily over the age of 70 (80%), will develop GCA every year.5 GCA is a medical emergency, requiring prompt diagnosis and treatment due to the risk of sudden, irreversible vision loss and stroke.6 7 GCA is more prevalent among people of northern European descent, with women being significantly more affected than men.8","length":533,"tagName":"p"},{"type":"text","content":""Steroids have been the mainstay of GCA therapy, but t...